Prognostic factors and benefits of adjuvant therapy after pancreatoduodenectomy for ampullary adenocarcinoma: Mayo Clinic experience

Zhaohui Jin, Mindy L. Hartgers, Cristobal T. Sanhueza, Christopher R. Shubert, Steven Robert Alberts, Mark Truty, Prasuna Muppa, David M. Nagorney, Thomas Christopher Smyrk, Mohamed Hassan, Amit Mahipal

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Introduction: Ampullary adenocarcinoma is a rare entity with limited data on prognostic factors. The aim of this study is to identify prognostic factors and assess the benefit of adjuvant therapy in patients with ampullary adenocarcinoma who underwent pancreatoduodenectomy. Methods: A cohort of 121 consecutive patients underwent pancreatoduodenectomy for ampullary adenocarcinoma from 2006 to 2016 at Mayo Clinic in Rochester, MN. All patients were confirmed by independent pathologic review to have ampullary carcinoma. Patient survival and its correlation with patient and tumor variables were evaluated by univariate and multivariate analysis. Results: Fifty three patients (45%) received adjuvant therapy (34 patients had chemotherapy alone, while 19 patients received both chemotherapy and radiation therapy). Fifty seven percent of the patients were diagnosed with advanced stage disease (Stage IIB or higher). Nearly all patients (98.3%) had negative surgical margins. Median overall survival (OS) was 91.8 months (95% CI:52.6 months-not reached). In multivariate analysis, excellent performance status (ECOG: 0), adjuvant therapy, and advanced stage remained statistically significant. Adjuvant therapy was independently associated with improved disease free survival (Hazard ratio [HR]:0.52, P = 0.04) and overall survival (HR:0.45, P = 0.03) in patients with advanced disease. Conclusions: Adjuvant therapy was associated with improved survival in patients with resected ampullary cancer, especially with advanced stage disease. A multi-institutional randomized trial is needed to further assess the role of adjuvant therapy in ampullary adenocarcinoma.

Original languageEnglish (US)
JournalEuropean Journal of Surgical Oncology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Pancreaticoduodenectomy
Adenocarcinoma
Therapeutics
Survival
Multivariate Analysis
Drug Therapy
Disease-Free Survival
Neoplasms
Radiotherapy

Keywords

  • Adjuvant
  • Ampulla of vater
  • Chemotherapy
  • Pancreaticoduodenectomy

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Prognostic factors and benefits of adjuvant therapy after pancreatoduodenectomy for ampullary adenocarcinoma : Mayo Clinic experience. / Jin, Zhaohui; Hartgers, Mindy L.; Sanhueza, Cristobal T.; Shubert, Christopher R.; Alberts, Steven Robert; Truty, Mark; Muppa, Prasuna; Nagorney, David M.; Smyrk, Thomas Christopher; Hassan, Mohamed; Mahipal, Amit.

In: European Journal of Surgical Oncology, 01.01.2018.

Research output: Contribution to journalArticle

Jin, Zhaohui ; Hartgers, Mindy L. ; Sanhueza, Cristobal T. ; Shubert, Christopher R. ; Alberts, Steven Robert ; Truty, Mark ; Muppa, Prasuna ; Nagorney, David M. ; Smyrk, Thomas Christopher ; Hassan, Mohamed ; Mahipal, Amit. / Prognostic factors and benefits of adjuvant therapy after pancreatoduodenectomy for ampullary adenocarcinoma : Mayo Clinic experience. In: European Journal of Surgical Oncology. 2018.
@article{fb3b86535cda40ed8b053b29f0851a47,
title = "Prognostic factors and benefits of adjuvant therapy after pancreatoduodenectomy for ampullary adenocarcinoma: Mayo Clinic experience",
abstract = "Introduction: Ampullary adenocarcinoma is a rare entity with limited data on prognostic factors. The aim of this study is to identify prognostic factors and assess the benefit of adjuvant therapy in patients with ampullary adenocarcinoma who underwent pancreatoduodenectomy. Methods: A cohort of 121 consecutive patients underwent pancreatoduodenectomy for ampullary adenocarcinoma from 2006 to 2016 at Mayo Clinic in Rochester, MN. All patients were confirmed by independent pathologic review to have ampullary carcinoma. Patient survival and its correlation with patient and tumor variables were evaluated by univariate and multivariate analysis. Results: Fifty three patients (45{\%}) received adjuvant therapy (34 patients had chemotherapy alone, while 19 patients received both chemotherapy and radiation therapy). Fifty seven percent of the patients were diagnosed with advanced stage disease (Stage IIB or higher). Nearly all patients (98.3{\%}) had negative surgical margins. Median overall survival (OS) was 91.8 months (95{\%} CI:52.6 months-not reached). In multivariate analysis, excellent performance status (ECOG: 0), adjuvant therapy, and advanced stage remained statistically significant. Adjuvant therapy was independently associated with improved disease free survival (Hazard ratio [HR]:0.52, P = 0.04) and overall survival (HR:0.45, P = 0.03) in patients with advanced disease. Conclusions: Adjuvant therapy was associated with improved survival in patients with resected ampullary cancer, especially with advanced stage disease. A multi-institutional randomized trial is needed to further assess the role of adjuvant therapy in ampullary adenocarcinoma.",
keywords = "Adjuvant, Ampulla of vater, Chemotherapy, Pancreaticoduodenectomy",
author = "Zhaohui Jin and Hartgers, {Mindy L.} and Sanhueza, {Cristobal T.} and Shubert, {Christopher R.} and Alberts, {Steven Robert} and Mark Truty and Prasuna Muppa and Nagorney, {David M.} and Smyrk, {Thomas Christopher} and Mohamed Hassan and Amit Mahipal",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.ejso.2018.02.008",
language = "English (US)",
journal = "European Journal of Surgical Oncology",
issn = "0748-7983",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Prognostic factors and benefits of adjuvant therapy after pancreatoduodenectomy for ampullary adenocarcinoma

T2 - Mayo Clinic experience

AU - Jin, Zhaohui

AU - Hartgers, Mindy L.

AU - Sanhueza, Cristobal T.

AU - Shubert, Christopher R.

AU - Alberts, Steven Robert

AU - Truty, Mark

AU - Muppa, Prasuna

AU - Nagorney, David M.

AU - Smyrk, Thomas Christopher

AU - Hassan, Mohamed

AU - Mahipal, Amit

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Introduction: Ampullary adenocarcinoma is a rare entity with limited data on prognostic factors. The aim of this study is to identify prognostic factors and assess the benefit of adjuvant therapy in patients with ampullary adenocarcinoma who underwent pancreatoduodenectomy. Methods: A cohort of 121 consecutive patients underwent pancreatoduodenectomy for ampullary adenocarcinoma from 2006 to 2016 at Mayo Clinic in Rochester, MN. All patients were confirmed by independent pathologic review to have ampullary carcinoma. Patient survival and its correlation with patient and tumor variables were evaluated by univariate and multivariate analysis. Results: Fifty three patients (45%) received adjuvant therapy (34 patients had chemotherapy alone, while 19 patients received both chemotherapy and radiation therapy). Fifty seven percent of the patients were diagnosed with advanced stage disease (Stage IIB or higher). Nearly all patients (98.3%) had negative surgical margins. Median overall survival (OS) was 91.8 months (95% CI:52.6 months-not reached). In multivariate analysis, excellent performance status (ECOG: 0), adjuvant therapy, and advanced stage remained statistically significant. Adjuvant therapy was independently associated with improved disease free survival (Hazard ratio [HR]:0.52, P = 0.04) and overall survival (HR:0.45, P = 0.03) in patients with advanced disease. Conclusions: Adjuvant therapy was associated with improved survival in patients with resected ampullary cancer, especially with advanced stage disease. A multi-institutional randomized trial is needed to further assess the role of adjuvant therapy in ampullary adenocarcinoma.

AB - Introduction: Ampullary adenocarcinoma is a rare entity with limited data on prognostic factors. The aim of this study is to identify prognostic factors and assess the benefit of adjuvant therapy in patients with ampullary adenocarcinoma who underwent pancreatoduodenectomy. Methods: A cohort of 121 consecutive patients underwent pancreatoduodenectomy for ampullary adenocarcinoma from 2006 to 2016 at Mayo Clinic in Rochester, MN. All patients were confirmed by independent pathologic review to have ampullary carcinoma. Patient survival and its correlation with patient and tumor variables were evaluated by univariate and multivariate analysis. Results: Fifty three patients (45%) received adjuvant therapy (34 patients had chemotherapy alone, while 19 patients received both chemotherapy and radiation therapy). Fifty seven percent of the patients were diagnosed with advanced stage disease (Stage IIB or higher). Nearly all patients (98.3%) had negative surgical margins. Median overall survival (OS) was 91.8 months (95% CI:52.6 months-not reached). In multivariate analysis, excellent performance status (ECOG: 0), adjuvant therapy, and advanced stage remained statistically significant. Adjuvant therapy was independently associated with improved disease free survival (Hazard ratio [HR]:0.52, P = 0.04) and overall survival (HR:0.45, P = 0.03) in patients with advanced disease. Conclusions: Adjuvant therapy was associated with improved survival in patients with resected ampullary cancer, especially with advanced stage disease. A multi-institutional randomized trial is needed to further assess the role of adjuvant therapy in ampullary adenocarcinoma.

KW - Adjuvant

KW - Ampulla of vater

KW - Chemotherapy

KW - Pancreaticoduodenectomy

UR - http://www.scopus.com/inward/record.url?scp=85042637487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042637487&partnerID=8YFLogxK

U2 - 10.1016/j.ejso.2018.02.008

DO - 10.1016/j.ejso.2018.02.008

M3 - Article

C2 - 29506768

AN - SCOPUS:85042637487

JO - European Journal of Surgical Oncology

JF - European Journal of Surgical Oncology

SN - 0748-7983

ER -